Research & Development (R&D)

Pharmaceutical R&D: Driving Innovation from Discovery to Development

Pharmaceutical R&D encompasses all scientific efforts involved in discovering, designing, developing, and optimizing a new drug or dosage form. It involves multidisciplinary teams, including chemists, biologists, pharmacologists, formulation scientists, clinical…

R&D Scale-Up Failures? Development-to-Manufacturing Solutions

Identifying early warning signals of scale-up failures is critical for effective intervention. Symptoms may manifest during various stages of the R&D process, including formulation development, stability testing, and the initial…

Design space poorly justified during comparability assessment – data package improvements for filing

Identifying symptoms of poorly justified design space during comparability assessments is crucial in instigating a thorough investigation. These signs may include:Click to read the full article.

Excipient variability impact during transfer to manufacturing – downstream GMP risk and prevention

A variety of signals can indicate issues stemming from excipient variability during the transfer process. Key symptoms to monitor include:Click to read the full article.

Formulation robustness underestimated during transfer to manufacturing – data package improvements for filing

Recognizing symptoms early is crucial for initiating appropriate responses during the transfer of formulations. Common signals that might indicate issues related to formulation robustness include:Click to read the full article.

Method development instability during pilot scale – how to ensure smooth tech transfer

The initial indication of method development instability can manifest through several symptoms during pilot-scale operations. Recognizing these symptoms is crucial for timely intervention. Common signals include:Click to read the full…

Excipient variability impact during pilot scale – downstream GMP risk and prevention

Recognizing symptoms of excipient variability is fundamental in identifying potential risks during the pilot-scale phase. Symptoms may present in various forms, including:Click to read the full article.

Excipient variability impact during comparability assessment – regulatory scrutiny implications

Identifying the initial signals of excipient variability is crucial for timely intervention. Symptoms may include:Click to read the full article.

Tech transfer readiness gaps during transfer to manufacturing – regulatory scrutiny implications

Identifying symptoms or signals is the first step in addressing tech transfer readiness gaps. Common signs include:Click to read the full article.

Scale-up risk not identified during pilot scale – how to ensure smooth tech transfer

Identifying symptoms early is crucial to understanding if a scale-up risk has been overlooked during pilot production stages. Here are common signals to monitor during the pilot and initial scale-up…

Tech transfer readiness gaps during early development – downstream GMP risk and prevention

Addressing Readiness Gaps in Tech Transfer to Mitigate GMP Risks In the realm of pharmaceutical manufacturing, tech transfer during early development phases can present significant challenges. Often overlooked, these readiness…

Method development instability during transfer to manufacturing – data package improvements for filing

Recognizing early symptoms of method development instability is crucial in addressing potential compliance issues. Common signals include:Click to read the full article.